Admedus appoints new Chief Operating Officer
9, June, 2017
Posted In: Featured
Admedus Limited (Admedus) today announced the appointment of David St. Denis as the Company’s new Chief Operating Officer. He succeeds Julian Chick, who has recently resigned. St. Denis will take up the role in July after relocating to Minneapolis where he will be based. Read the full Company announcement here.
Admedus appoints new public relations consultancy
16, February, 2017
Admedus Limited (Admedus) today announced that Signal Leadership Communication Inc. (Signal) of Toronto has been appointed as its new public relations firm. Signal Principal Bob Pickard will personally serve as corporate communication counsel for Admedus. Read the full Company announcement here.
CardioCel: 8 years on and still free from calcification
23, August, 2016
CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]
Long-term CardioCel study shows no evidence of calcification after 8 years
22, August, 2016
Posted In: Uncategorized
Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.
Long-term study indicates no calcification with CardioCel after eight years
22, August, 2016
Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.
Using the ADAPT engineering process to create durable tissue scaffolds
8, July, 2016
Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]
Admedus a major distributor of infusion solutions
10, June, 2016
Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]